NCT07489300

Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Efficacy and safety of Benmelstobart combined with Anlotinib and oral metronomic Cyclophosphamide in the treatment of recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (BACON study) in China

Conditions

• Ovarian Cancer
• Fallopian Tube Cancers
• Primary Peritoneal Cancer

Interventions

Type	Name	Description
DRUG	Benmelstobart in combination with Anlotinib and oral metronomic Cyclophosphamide	Benmelstobart in combination with Anlotinib and oral metronomic Cyclophosphamide in the treatment of recurrent epithelial OvariaN, fallopian tube, or primary peritoneal cancer

Timeline

• Start date: 2026-03-30
• Primary completion: 2027-01-31
• Completion: 2028-01-31
• First posted: 2026-03-24
• Last updated: 2026-03-24